Every Form 4 that Dermata Therapeutics Inc (DRMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DRMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMA filings page.
Dermata Therapeutics, Inc. (DRMA) reported that director and executive officer Gerald T. Proehl, through affiliated entities, acquired multiple warrant positions and common shares in a private placement exempt under Rule 16b-3(d)(1). Proehl Investment Ventures LLC received 1,360,544 Series E and 1,360,544 Series F warrants and 1,360,544 pre-funded warrants, each for common stock at exercise prices of $1.47 (Series E/F) and $0.001 (pre-funded). A family trust acquired 170,068 Series E, 170,068 Series F warrants and 170,068 common shares, increasing its indirect holdings to 292,631 shares. The warrants become exercisable only after stockholder approval and are subject to a 9.99% beneficial ownership cap, and the reporting person disclaims beneficial ownership beyond pecuniary interest.
Dermata Therapeutics, Inc. (DRMA) reported that its SVP and CFO, Kyri K. Van Hoose, acquired securities in a private placement. She acquired 102,040 shares of common stock and now directly holds 232,463 common shares. In the same transaction, she received a Series E Warrant and a Series F Warrant, each for 102,040 underlying common shares at an exercise price of $1.47 per share. The common stock and accompanying warrants were purchased together at $1.47 per unit. The warrants become exercisable on the effective date of required stockholder approval, are capped at 9.99% beneficial ownership, and expire five years (Series E) and two years (Series F) after that approval.
Dermata Therapeutics director Kathleen D. Scott reported a small open-market sale of common stock. She sold 11 shares of Dermata Therapeutics, Inc. common stock in an open-market transaction at a price of $1.1901 per share. After this sale, she held no shares directly but reported indirect ownership of 1 share held by the Scott 2008 Trust Dated 3/28/08.
Dermata Therapeutics, Inc. senior vice president of regulatory affairs Maria E. Bedoya-Toro Munera bought 1,000 shares of common stock in an open-market transaction at $1.27 per share on February 17, 2026. Following this purchase, she holds 1,012 shares directly and 34 shares indirectly through the Munera Family Trust.
Dermata Therapeutics director David F. Hale reported a new stock option grant. On 01/02/2026, he was awarded a stock option to buy 2,500 shares of Dermata Therapeutics, Inc. common stock at an exercise price of $2.18 per share.
The option vests in twelve substantially equal monthly installments, with the first installment vesting one month after the grant date, as long as he remains in continuous service through each vesting date. Following this grant, he beneficially owns 2,500 derivative securities directly.
Dermata Therapeutics, Inc. director Kathleen D. Scott reported receiving a grant of stock options. The award covers 2,500 Stock Options (Right to Buy) Dermata common shares at an exercise price of $2.18 per share, with no cash paid at grant. These options were granted on 01/02/2026 and are held directly.
The options will vest in twelve equal monthly installments, with the first installment vesting one month after the grant date and additional portions vesting monthly thereafter, as long as Scott continues to serve the company through each vesting date. The options are scheduled to expire on 01/01/2036, and the filing shows 2,500 derivative securities beneficially owned following this transaction.
Dermata Therapeutics executive Christopher J. Nardo, Senior VP and Chief Development Officer, reported a new equity award in the form of stock options. On January 2, 2026, he was granted an option to purchase 18,000 shares of Dermata Therapeutics common stock at an exercise price of $2.18 per share. The filing states that 25% of the shares underlying the option will vest on the 12‑month anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments starting on that same 12‑month anniversary. Following this grant, he beneficially owns stock options for 18,000 shares, held as direct ownership.
Dermata Therapeutics director Andrew Seth Sandler received a grant of stock options for 2,500 shares on January 2, 2026. The options have an exercise price of $2.18 per share and expire on January 1, 2036. They vest in twelve substantially equal monthly installments, starting one month after the grant date, contingent on his continuous service. Following this award, he beneficially owned 2,500 derivative securities directly.
Dermata Therapeutics director Brittany Bradrick reported a new equity award. On January 2, 2026, she was granted a stock option to buy 2,500 shares of common stock at $2.18 per share. The option was received at no cost and is held directly. Following this grant, she beneficially owns 2,500 derivative securities in the form of this option.
According to the vesting terms, the 2,500 underlying shares vest in twelve substantially equal monthly installments. The first installment vests on the one‑month anniversary of the grant date, with additional installments vesting monthly thereafter, as long as she continues in service through each vesting date.